In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.
Advertisement
Set Alert for Articles By Ian Haydock

Latest From Ian Haydock

Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads

As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.

Japan Research & Development

Innovation Ecosystem Needs More Support, BioJapan Hears

Head of industry group in Japan makes personal plea at major biotech meeting for improvements to Japan’s innovation ecosystem, as government representatives say steps are already being taken to improve collaborative research and foster bioventures.

Japan Innovation

Singapore's DotBio Begins Play For Antibody Domain

Emerging Company Profile: Newly formed Singapore venture DotBio aims to develop novel immuno-oncology therapies based on optimized, multi-specific humanized domain antibodies, with a focus on targeting checkpoint blockades, positive immune signals and tumor-specific processes in oncology.

Singapore Biologics

Asia Deal Watch: Alvotech Signs On To Biosimilar Manufacturing JV In China

With partner CCHN, Alvotech will help finance construction of a biologics facility in Changchun, China. Novartis will work with Cellular Biomedicine to produce Kymriah for China, and will gain access to its CAR-T platform.

Deals Commercial

Whiz Looks To Axcelead To Help Build Lagging Japan Venture Ecosystem

Japan was never known for its healthcare-focused venture capital funds, but Whiz Partners, Inc. is looking to fill what it sees as a void, helped by some heavy corporate hitters, and a major new collaboration with Takeda's spun out preclinical development operations in Japan.

Japan Commercial

Master Key Project Aims To Unlock Japan Rare Cancer Drug Development

Japan's National Cancer Center is progressing a collaborative project with industry to encourage the development of targeted therapies for rare cancers, as part of wider efforts to support early access to personalized oncology drugs.

Japan Cancer
See All
Advertisement
UsernamePublicRestriction

Register